HCAb Harbour Mice® Advances Multispecific, CART, and ADC Therapy in a New Level

HCAb Harbour Mice® Advances Multispecific, CART, and ADC Therapy in a New Level

Monday, April 15, 2024 5:30 PM to 5:50 PM · 20 min. (US/Pacific)
Bispecifics & Multispecifics - sponsored by Cytiva
Presentation
Room 3

Information

HCAb Harbour Mice® of Nona Biosciences is the first fully human heavy chain only antibody (HCAb) transgenic mice platform in history. It is optimized, clinically validated with global patent protection. HCAb Harbour Mice® efficiently produces high affinity, and functional HCAbs with excellent biophysical characteristics. Fully human heavy chain only antibodies are the ideal antibody format to generate a multitude of next-generation therapeutic modalities including bispecific/multispecific antibodies, CART, ADC, and mRNA therapy.

Nona BiosciencesBooth 339Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovation and provides a total solution from “Idea to IND” (I to I™), ranging from target validation and antibody discovery through preclinical research. The integrated antibody discovery services range from antigen preparation, animal immunization, highly robust antibody screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® technology and the experienced therapeutic antibody discovery team. Harbour Mice® generate fully human monoclonal antibodies in a traditional two heavy and two light chain (H2L2) format, and a heavy chain only (HCAb) format. Integrating Harbour Mice® with highly robust antibody screening platforms, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs.

Log in